Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors reduce bodyweight (BW) by creating a negative energy balance. Previous reports have suggested that this BW reduction is mainly loss of body fat and that ~20% of the reduction is lean mass. However, the effects of sodium–glucose cotransport...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Hideka, Morino, Katsutaro, Ugi, Satoshi, Tanaka‐Mizuno, Sachiko, Fuse, Keiko, Miyazawa, Itsuko, Kondo, Keiko, Sato, Daisuke, Ohashi, Natsuko, Ida, Shogo, Sekine, Osamu, Yoshimura, Masahiro, Murata, Kiyoshi, Miura, Katsuyuki, Arima, Hisatomi, Maegawa, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626939/
https://www.ncbi.nlm.nih.gov/pubmed/30536746
http://dx.doi.org/10.1111/jdi.12985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626939/
https://www.ncbi.nlm.nih.gov/pubmed/30536746
http://dx.doi.org/10.1111/jdi.12985

Ejemplares similares